This is an aggregated industry headline. Read the full story at FierceBiotech →
Novartis to pay $1.1B upfront for UK biotech Myricx to expand the pharma's ADC pipeline
Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload.
By FierceBiotech
· Jul 6, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
After a site visit by FDA inspectors yielded a Form 483 for Genzyme Ireland in early 2026, the Sanofi subsidia…
The WeekBriefing
The FDA has granted premarket approval to United Therapeutics' LungFX device, designed to assess donor lungs f…
The WeekPharmaceutical Technology ↗
Roche's breast cancer agreement with Astex is one of several oncology deals the Swiss pharma giant has inked i…